207 - Ex vivo Assessment of Cefepime (FEP) Clearance during Continuous Renal Replacement Therapy (CRRT) and Clinical Validation of Optimized Dosing Regimens

Thursday, October 17, 2024

3:15 PM – 3:30 PM US PT

Location: 403 B

Presenting Author(s)

Christina Konig, PhD (she/her/hers)

ID Fellow
Hartford Hospital
Hartford, Connecticut, United States

Slides

Co-Author(s)

CM

Cole McGrath, B.S

Hartford Hospital
Hartford, Connecticut, United States
HR

Hanna Roenfanz, PhD

Associate Director, Analytical Sciences
Hartford Hospital
Hartford, Connecticut, United States
YS

Yuwei Shen, PharmD

Hartford Hospital
Hartford, Connecticut, United States
DN

David P. Nicolau, PharmD

Director
Hartford Hospital
Hartford, Connecticut, United States
Joseph L. Kuti, PharmD

Associate director
Hartford Hospital
Hartford, CT, United States

Disclosure(s):

Christina Konig, PhD: Gilead Inc.: Honoraria; Pfizer Inc.: Honoraria; Shionogi Inc.: Honoraria

Cole McGrath, B.S: No financial relationships to disclose

Hanna Roenfanz, PhD: No financial relationships to disclose

Yuwei Shen, PharmD: No financial relationships to disclose

David P. Nicolau, PharmD: CARB-X: Grant/Research Support; Innoviva: Grant/Research Support, Honoraria; Merck: Advisor/Consultant, Grant/Research Support, Honoraria; Pfizer: Advisor/Consultant, Grant/Research Support, Honoraria; Shionogi: Advisor/Consultant, Grant/Research Support, Honoraria; Venatorx: Grant/Research Support

Joseph L. Kuti, PharmD: Abbvie: Advisor/Consultant; bioMerieux: Grant/Research Support; Merck: Grant/Research Support; Pfizer: Grant/Research Support; Shionogi Inc: Advisor/Consultant, Grant/Research Support, Honoraria; Venatorx: Grant/Research Support